ESC Premium Access

Cancer incidence during follow-up in patients with new-onset atrial fibrillation treated with DOACs and its impact on bleeding risk

Presentation

About the speaker

Doctor Francesco Angeli

Bozzano (Italy)
0 follower

160 more presentations in this session

The impact of abnormal conduction zone on outcomes after catheter ablation for atrial fibrillation

Speaker: Associate Professor T. Mine (Hyogo, JP)

Thumbnail

Thromboembolic risk of movable type left atrial appendage thrombi in patients with atrial fibrillation under widespread use of anticoagulants

Speaker: Doctor M. Sugitani (Nishinomiya, JP)

Thumbnail

Rate and rhythm control treatment in the elderly and very elderly patients with atrial fibrillation: an observational cohort study of 1,497 patients

Speaker: Mr T. Klamer (Amsterdam, NL)

Thumbnail

One year outcome and analysis of peri-device leak of left atrial appendage occlusion devices

Speaker: Doctor M. Mansour (Montreal, CA)

Thumbnail

Risk prediction of atrial fibrillation and its complications in the community using high-sensitivity cardiac Troponin I: Results from the BiomarCaRE Consortium

Speaker: Doctor C. Boerschel (Hamburg, DE)

Thumbnail

Access the full session

Atrial fibrillation e-posters

Speakers: Doctor F. Angeli, Associate Professor T. Mine, Doctor M. Sugitani, Mr T. Klamer, Doctor M. Mansour...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

2MACE score predicts cardiovascular adverse events in real-world atrial fibrillation patients under rivaroxaban therapy. Data from EMIR study

27 August 2021

ESC Premium Access

Association between renal function and clinical outcomes in elderly patients with nonvalvular atrial fibrillation: sub-analysis of the ANAFIE Registry

27 August 2021

ESC Premium Access

Clinical benefit of direct oral anticoagulants vs. vitamin-K antagonist in octogenarians with atrial fibrillation

27 August 2021

This platform is supported by

logo Novo Nordisk